Literature DB >> 29987681

A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung.

Junna Hou1, Lihua Xing2, Yufen Yuan3.   

Abstract

The aim was to investigate the clinicopathological characteristics, diagnosis, and prognosis of sarcomatoid carcinoma of the lung. We reviewed 114 cases of sarcomatoid carcinoma of the lung in patients that were admitted to the First Affiliated Hospital of Zhengzhou University and Anyang Tumor Hospital from January 2009 to March 2018. We analyzed the clinical characteristics, immunohistochemical profiles, treatments, and overall survival of the patients. The patient population included 88 men and 26 women. Median patient age was 65 years (range 37-88 years), and the gender ratio (M/F) was 3.4:1. Median survival was 3.5 months (range 0.5-60 months). Univariate analysis showed that tumor location, tumor size, M stage, TNM stage, chemotherapy, and surgery were all prognostic factors for survival (P < 0.05). We found that T stage, surgery, and chemotherapy were independent prognostic factors for sarcomatoid carcinoma (P < 0.05). Pulmonary sarcomatoid carcinoma is a rare tumor with a poor prognosis. Patients with smaller T stage, complete resection, and chemotherapy exhibited a better prognosis. Early diagnosis and early treatment are important to improve the prognosis of these patients.

Entities:  

Keywords:  Clinical pathology; Lung cancer; Sarcomatoid carcinoma; Survival analysis; Treatment response

Mesh:

Year:  2018        PMID: 29987681     DOI: 10.1007/s10238-018-0517-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  2 in total

1.  Carcinosarcoma of the lung.

Authors:  T C MOORE
Journal:  Surgery       Date:  1961-12       Impact factor: 3.982

2.  Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases.

Authors:  Takahiro Mochizuki; Genichiro Ishii; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Tetsuya Mizuno; Tomoyuki Yokose; Kazuya Suzuki; Atsushi Ochiai
Journal:  Am J Surg Pathol       Date:  2008-11       Impact factor: 6.394

  2 in total
  9 in total

1.  PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.

Authors:  Zhenlin Yang; Jiachen Xu; Renda Li; Yibo Gao; Jie He
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-14       Impact factor: 4.553

2.  Epidemiology of and prognostic factors for patients with sarcomatoid carcinoma: a large population-based study.

Authors:  Zihan Xu; Li Wang; Li Tu; Yanyang Liu; Xiaoxiao Xie; Xiaojun Tang; Feng Luo
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

3.  Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma.

Authors:  Jiachun Sun; Zhiyi Jiang; Tanyou Shan; Ruina Yang; Dejiu Kong; Junshuai Rui; Xinyang Li; Guoqiang Kong; Baoping Chang
Journal:  Front Oncol       Date:  2022-05-03       Impact factor: 5.738

4.  Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma.

Authors:  Qingpeng Zeng; Jiagen Li; Nan Sun; Qi Xue; Yushun Gao; Jun Zhao; Yousheng Mao; Juwei Mu; Dali Wang; Shugeng Gao; Jie He
Journal:  Transl Lung Cancer Res       Date:  2021-01

5.  Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.

Authors:  Ziwei Liang; Enyu Zhang; Ling Duan; Nathaniel Weygant; Guangyu An; Bin Hu; Jiannan Yao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art.

Authors:  Lin Zhang; Weihao Lin; Zhenlin Yang; Renda Li; Yibo Gao; Jie He
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375

7.  Pulmonary Carcinosarcoma: A Rare Disease With Challenging Diagnosis and Treatment.

Authors:  Erinie Mekheal; Ashima Kapoor; Sherif Roman; Nader Mekheal; Christopher Millet; Marina Mekheal; Michael Maroules
Journal:  Cureus       Date:  2022-07-15

8.  Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre.

Authors:  Suresh Kumar Bondili; Ravindra Nandhana; Aditya Dhanawat; Vanita Noronha; Amit Joshi; Vijay Maruti Patil; Nandini Menon; Rajiv Kumar Kaushal; Anuradha Choughule; Sabita S Jiwnani; Amit Janu; Kumar Prabhash
Journal:  Ecancermedicalscience       Date:  2022-08-08

Review 9.  First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature.

Authors:  Feng-Wei Kong; Wei-Min Wang; Lei Liu; Wen-Bin Wu; Xiang Wang; Miao Zhang
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.